First-line eradication of H pylori infection in Europe: A meta-analysis based on congress abstracts, 1997-2004

Table 2 Results of the direct comparative trials of the PPI-based 1-wk triple combinations

PPI comparation	Cases (n)	Studies (n)	Treatmentarms (n)	PER95% CI	P	OR (95% CI)	References
Omeprazole vs	601	5	9	87.3 (81.7-92.3)	0.22	0.83 (0.6-1.1)	32-37, 39
Lansoprazole	567	5	9	83.9 (75.0-92.3)
Omeprazole vs	83	1	1	89.0 (80.9-97.6)	0.24	0.61 (0.27-1.40)	39
Pantoprazole	85	1	1	79.6 (71.5-87.6)
Omeprazole vs	253	2	2	90.5 (84.6-96.4)	0.71	0.91 (0.53-1.55)	43, 44
Esomeprazole	256	2	2	91.5 (86.3-96.7)
Omeprazole vs	163	1	2	82.5 (74.2-90.8)	0.61	1.24 (1.00-1.48)	53
Rabeprazole	163	1	2	88.5 (81.3-95.7)

Test of homogeneity: Omeprazole/Lansoprazole, χ² = 2.76, P = 0.1; Omeprazole/Pantoprazole, χ² = 2.69, P = 0.12; Omeprazole/Rabeprazole, χ² = 2.45, P = 0.12; Omeprazole/Esomeprazole, χ² = 0.12, P = 0.72.